Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus

Cancer

Volumn 88, Issue 7, 2000, Pages 1650-1662

  Graham, Viviana Valadez ^a   Sutter, Gerd ^b   José, Marco V ^a   García Carranca, Alejandro ^a   Erfle, Volker ^b   Mendoza, Norma Moreno ^a   Merchant, Horacio ^a   Rosales, Ricardo ^a,c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Cervical carcinoma; MVA strain; Papillomavirus; Vaccinia virus

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; PAPILLOMAVIRUS E2 PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT;

3T3 CELLS; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; CELL LINE; CHICK EMBRYO; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; GENE THERAPY; HELA CELLS; HUMANS; MALE; MICE; MICE, NUDE; MODELS, GENETIC; NEOPLASM TRANSPLANTATION; PLASMIDS; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 0034177497     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000401)88:7<1650::AID-CNCR20>3.0.CO;2-L     Document Type: Article

References (50)

1. Beaudenon S, Kremsdorf D, Croissant O, Jablonska S, Wain-Hobson S, Orth G. A novel type of papillomavirus associated with genital neoplasias. Nature 1986;321:246-9.
2. Beaudenon S, Kremdorf D, Obalek S, Jablonska S, Pehau-Arnaudet G, Croissant O, et al. Plurality of genital human papillomaviruses: characterization of two new types with distinct biological properties. Virology 1987;161:374-84.
3. Lörincz AT, Quinn AP, Lancaster WD, Temple GF. A new type of papillomavirus associated with cancer of the uterine cervix. Virology 1987;159:187-90.
4. Cuzick J, Terry G, Ho L. Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer. Lancet 1992;339:959-60.
5. Bosch FX, Muñoz N, de Sanjosé S. Human papillomavirus and other risk factors for cervical cancer. Biomed Pharmacother 1997;51:268-75.
6. Muñoz N, Kato I, Bosch FX, Eluf Neto J, De Sanjosé S, Ascunce N, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:504-10.
7. Muñoz N, Bosch FX. Cervical cancer and human papillomavirus: epidemiological evidence and perspectives for prevention. Salud Publica Mex 1997;39:274-82.
8. Nuovo GJ, Friedman D, Richart RM. In situ hybridization analysis of human papillomavirus DNA segregation patterns in lesions of the female genital tract. Gynecol Oncol 1990;36: 256-62.
9. Cullen AP, Reid R, Campion M, Lörincz A. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991; 65:606-12.
10. Dürst M, Gissmann L, Ikenberg H, zur Hausen HA. Papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983;80:3812-5.
11. zur Hausen H, Schneider A. The role of papillomavirus in human anogenital cancer. In: Salzman NP, Mltowley P. The papillomaviruses. New York: Plenum Press, 1987;245-63.
12. De Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol 1994;186:1-12.
13. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989;172:63-72.
14. Guido MC, Zamorano R, Garrido-Guerrero E, Gariglio P, García-Carranca A. Early promoters of genital and cutaneous human papillomaviruses are differentially regulated by the bovine papillomavirus type 1 E2 gene product. J Gen Virol 1992;73:1395-400.
15. Hwang ES, Riese DJ, Settleman J, Nilson CA, Honig J, Flynn S, et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol 1993;67:3720-9.
16. Thierry F, Howley PM. Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol 1991;3: 90-100.
17. Berumen J, Casas L, Segura E, Amezcua J, García-Carranca A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas in related to retention of E1/E2 genes. Int J Cancer 1994;56:640-5.
18. Fuchs P, Giardi F, Pfister H. Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for early metastases? Int J Cancer 1989;43:41-4.
19. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Small-pox and its erradication. Geneva: World Health Organization, 1988.
20. Mayr A, Hochstein-Mintzel V, Stickl H. Infection 1975;3:6-14.
21. Mayr A, Stickl H, Multer HK, Danner K, Singer H. Zbl Bakt Hyg I Abt Orig B 1978;167:375-90.
22. Shingu M, Chinami M, Taguch C, Shingu MJ. Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia. J Gen Virol 1991;72:2031-4.
23. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-1085.
24. Sutter G, Ohlmann M, Erfle V. Non-replicating vector efficiently expresses bacteriophage T7 polymerase. Febs Lett 1995;371:9-12.
25. Lathe R, Kieny MP, Gerlinger P, Clertant P, Guzani I, Cuzin F, et al. Tumor prevention and rejection with recombinant vaccinia. Nature 1987;326:878-80.
26. Sutter G, Wyatt LS, Foley PL, Bennick JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:53-9.
27. Dowhanick JJ, McBride AA, Howley PM. Supression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995;69:7791-9.
28. 105 promoters. J Virol 1990; 64:2849-59.
29. Yang Y-C, Okayama H, Howley PM. Bovine papillomavirus contains multiple transforming genes. Proc Natl Acad Sci U S A 1985;82:1030-4.
30. Chirgwin JM, Przybyla AE, McDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid form sources enriched in ribonuclease. Biochemistry 1979;18:5294-7.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye. Anal Biochem 1976;72:248-54.
32. Miller JH. Experiments in molecular genetics. New York: Cold Spring Harbor Laboratory, 1972.
33. Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 1994; 56:259-321.
34. Draper NR, Smith H. Applied regression analysis. New York: John Wiley & Sons, Inc., 1981.
35. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques. Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70: 3741-52.
36. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schsfer H, Holzner A. MVA - Stufenimpfung gegen Pocken. Dtsch Med Wochenschr 1974;99:2386-92.
37. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997;16:504-14.
38. Lörincz AT, Temple GF, Kurman RJ, Jenson AB, Lancaster WD. Oncogenic association of specific human papillomavirus type with cervical neoplasia. J Natl Cancer Inst 1987;79: 671-7.
39. Baker CC, Phelps WC, Lingren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987;64:962-71.
40. Dostatni C, Lambert PF, Sousa R, Ham J, Howley PM, Yaniv M. The functional BPV-1 E2 trans-activating protein can act as a represser by preventing formation of the initiation complex. Genes Dev 1991;69:1657-71.
41. Thierry F, Yaniv M. The BPV1-E2 trans-acting protein can be either an activator or a represser of the HPV18 regulatory region. EMBO J 1987;6:3391-7.
42. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid P, Dürst M, et al. Transcriptional regulation of the human papillomavirus E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene product: implications for cervical carcinogenesis. EMBO J 1987;6:3745-53.
43. Schneider-Gädicke A, Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 1986;5: 2285-92.
44. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia virus expressing E6 and E7. Virology 1991;181:62-9.
45. Selvey LA, Dunn LA, Tindle RW, Park DS, Frazer IH. Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. J Gen Virol 1994;75:1647-53.
46. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-7.
47. Binns MM, Smith GL. Recombinant poxvirus. Boca Raton, Florida: ACR Press, 1993.
48. Fujimaru T. Virus as an aid to cancer therapy: selective method of more effective oncolytic bovine enterovirus. J Kurum Med Assoc 1978;41:15-32.
49. Meneguzzi G, Kieny MP, Lecocq JP, Chambon P, Cuzin F, Lathe R. Vaccinia recombinants expressing early bovine papillomavirus (BPV1) proteins: retardation of BPV1 tumor development. Vaccine 1990;8:199-206.
50. Selvakumar R, Borenstein LA, Lin YL, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 1994;69:602-5.